NZ591008A - Purin derivatives for use in the treatment of fab-related diseases - Google Patents

Purin derivatives for use in the treatment of fab-related diseases

Info

Publication number
NZ591008A
NZ591008A NZ591008A NZ59100809A NZ591008A NZ 591008 A NZ591008 A NZ 591008A NZ 591008 A NZ591008 A NZ 591008A NZ 59100809 A NZ59100809 A NZ 59100809A NZ 591008 A NZ591008 A NZ 591008A
Authority
NZ
New Zealand
Prior art keywords
methyl
fab
treatment
compounds
related diseases
Prior art date
Application number
NZ591008A
Inventor
Thomas Klein
Michael Mark
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to NZ604091A priority Critical patent/NZ604091A/en
Priority claimed from PCT/EP2009/060521 external-priority patent/WO2010018217A2/en
Publication of NZ591008A publication Critical patent/NZ591008A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ABSTRACT - 591008 The disclosure relates to the use of a DPP-4 inhibitor such as 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine, which is represented by either of the formulae (I), (II), (III) or (IV) and pharmaceutically acceptable salt, wherein the variables are as defined in the specification. These compounds are suitable for wound healing preferably in diabetic patients, or for reducing destructive wound inflammation, such as e.g. for reducing the number of polymorphonuclear neutrophils (PMN), particularly of diabetes-associated wounds. Also disclosed is the use of these compounds in combination with one or more other therapeutically active agents selected from metformin, pioglitazone and telmisartan, for separate, sequential, simultaneous, concurrent or chronologically staggered use in wound healing.
NZ591008A 2008-08-15 2009-08-13 Purin derivatives for use in the treatment of fab-related diseases NZ591008A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ604091A NZ604091A (en) 2008-08-15 2009-08-13 Purin derivatives for use in the treatment of fab-related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08060740 2008-08-15
EP09150252 2009-01-08
EP09160682 2009-05-19
PCT/EP2009/060521 WO2010018217A2 (en) 2008-08-15 2009-08-13 Organic compounds for wound healing

Publications (1)

Publication Number Publication Date
NZ591008A true NZ591008A (en) 2013-06-28

Family

ID=48670214

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591008A NZ591008A (en) 2008-08-15 2009-08-13 Purin derivatives for use in the treatment of fab-related diseases

Country Status (2)

Country Link
CL (1) CL2011000328A1 (en)
NZ (1) NZ591008A (en)

Also Published As

Publication number Publication date
CL2011000328A1 (en) 2011-06-17

Similar Documents

Publication Publication Date Title
NZ593754A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients
Zank et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics
NZ605207A (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
NZ590787A (en) DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy
WO2010018217A3 (en) Purin derivatives for use in the treatment of fab-related diseases
NZ625577A (en) Therapeutic uses of pharmaceutical compositions
WO2009044392A3 (en) Novel sirna structures
US9526728B2 (en) Medical use of a DPP-4 inhibitor
RS53272B (en) Uses of dpp-iv inhibitors
NZ603319A (en) Diabetes therapy
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
CA2914791A1 (en) Dpp-4 inhibitors for treating diabetes and its complications
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
JP2016518438A5 (en)
NO20083004L (en) Use of benzofused heterocyclic sulfamide derivatives for the treatment of drug addiction
JP2012515176A (en) SGC stimulators or sGC activators in combination with PDE5 inhibitors for the treatment of erectile dysfunction
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
AR079057A1 (en) URINARY TRIAOSILCERAMIDE (GB3) AS A CARDIAC DISEASE MARKER
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
BR112014012054A2 (en) deferiprone treatment methods
MX345032B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 AUG 2016 BY SPRUSON + FERGUSON

Effective date: 20131121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2017 BY DENNEMEYER + CO.

Effective date: 20160722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2018 BY DENNEMEYER + CO

Effective date: 20170726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2019 BY DENNEMEYER + CO

Effective date: 20180803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2020 BY DENNEMEYER + CO.

Effective date: 20190719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200804

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2022 BY DENNEMEYER + CO.

Effective date: 20210802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2023 BY DENNEMEYER + CO. SARL.

Effective date: 20220801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230731